A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864)) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Project: Non Profit

Project Details

StatusActive
Effective start/end date3/1/192/28/25